Welcome to our dedicated page for EASTMAN CHEMICAL CO SEC filings (Ticker: EMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EASTMAN CHEMICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EASTMAN CHEMICAL CO's regulatory disclosures and financial reporting.
BlackRock, Inc. filed Amendment No. 16 to a Schedule 13G/A reporting beneficial ownership in Eastman Chemical Co. The filing states BlackRock's Reporting Business Units beneficially own 15,745,661 shares of Common Stock, representing 13.8% of the class. The filing lists 15,437,852 shares as sole voting power and identifies iShares Core S&P Small-Cap ETF as a holder with more than 5% of the class. The filing was signed by Spencer Fleming on 04/24/2026.
Eastman Chemical director Damon J. Audia reported routine compensation-related transactions involving cash-settled Phantom Stock Units tied to Eastman Chemical common stock. On April 8, 2026, he acquired 852 units at a reference value of $74.72 per unit and another 408 units. These units reflect voluntary and automatic deferrals of director retainer fees and reinvested dividend equivalents under the company’s Directors' Deferred Compensation Plan, and are payable only in cash after his board service ends. Following these awards, his balance increased to 2,646 Phantom Stock Units, with no open‑market share purchases or sales disclosed.
BUTLER ERIC L reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Eric L. Butler received a grant of 408 Phantom Stock Units as compensation. These units were credited under the Directors' Deferred Compensation Plan as an automatic deferral of a portion of his annual cash retainer fees.
Each Phantom Stock Unit tracks the market value of one share of Eastman Chemical common stock but is payable only in cash after he terminates service as a director. Following this grant and dividend equivalents reinvested in additional units, Butler now holds a total of 3,228 Phantom Stock Units under the plan.
BEGEMANN BRETT D reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Brett D. Begemann increased his deferred compensation balance through phantom stock units rather than cash fees. On April 8, 2026, he was credited with 1,159 Phantom Stock Units valued at $74.27 each and an additional 408 units at $0 under the company’s Directors' Deferred Compensation Plan. These units track the value of one share of Eastman common stock but are payable only in cash after his board service ends. Following these awards and fee deferrals, Begemann holds 58,408 phantom stock units directly, including amounts from voluntary and automatic fee deferrals and reinvested dividend equivalents.
Haynesworth Linnie M reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Linnie M. Haynesworth received 408 Phantom Stock Units on April 8, 2026, as a grant under the company’s Directors’ Deferred Compensation Plan. These units track the value of one share of Eastman common stock but are payable only in cash after board service ends.
The award increased Haynesworth’s Phantom Stock Unit balance to 5,640 units. The grant reflects an automatic deferral of a portion of the director’s annual retainer fees, with dividend equivalents reinvested into additional units, and does not represent an open-market stock purchase or sale.
OBRIEN JAMES J /KY reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director James J. O'Brien received 408 Phantom Stock Units credited under the company’s Directors' Deferred Compensation Plan. These units mirror the market value of one share of common stock each but are payable only in cash after he ceases serving as a director.
The award represents an automatic deferral of a portion of his annual retainer fees that would otherwise have been paid in cash. Following this grant, O'Brien holds a total of 18,137 Phantom Stock Units, which also include dividend equivalents that have been reinvested into additional units.
Alfonso Humberto P reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Humberto P. Alfonso reported two compensation-related grants of Phantom Stock Units tied to company common stock. On April 8, 2026, he was credited with 988 Phantom Stock Units at a reference value of $74.27 per unit and 408 additional units at $0.00 per unit.
After these transactions, his reported Phantom Stock Unit balance increased to 55,961 units. The footnotes explain these units are credited under the Directors' Deferred Compensation Plan, have a value equal to one share of Eastman Chemical common stock, and are payable only in cash after his service as a director ends.
The filing notes these units arise from a mix of voluntary deferral of retainer fees, automatic deferral of annual retainer fees into a director stock account, and dividend equivalents reinvested into additional Phantom Stock Units. These are administrative, non-market transactions rather than open-market share purchases or sales.
Holder Julie Fasone reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Julie Fasone Holder received 408 Phantom Stock Units as a compensation award. These units are credited under the Directors' Deferred Compensation Plan, with each unit valued like one share of Eastman common stock but payable only in cash after she leaves the board.
This grant arose from the automatic deferral of a portion of her annual director retainer that would otherwise have been paid in cash, and it also reflects dividend equivalents that are reinvested into additional Phantom Stock Units. Following this award, she now holds a total of 15,051 Phantom Stock Units.
SLAGER DONALD W reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company director Donald W. Slager received a compensation grant of 408 Phantom Stock Units. These units were credited under the Directors' Deferred Compensation Plan at no purchase price and each unit tracks the value of one share of common stock.
The award represents an automatic deferral of a portion of the director’s annual cash retainer, with amounts payable only in cash after his service as a director ends. Following this grant, Slager holds a total of 1,699 Phantom Stock Units, including units from prior awards and dividend equivalents reinvested in additional units.
HORNBAKER RENEE J reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company director Renee J. Hornbaker received an award of 408 Phantom Stock Units tied to the value of the company’s common stock. These units were credited under the Directors' Deferred Compensation Plan as an automatic deferral of a portion of her annual retainer fees.
Each Phantom Stock Unit is payable only in cash after she terminates service as a director and includes dividend equivalents reinvested into additional units. After this grant, she holds a total of 51,107 Phantom Stock Units.